CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2021.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
CARBON DIOXIDE, USP is an inhaled gas formulation approved by the FDA in October 2021 as an X-ray contrast agent. It functions through X-ray contrast activity to enhance radiological imaging. The product is indicated for use during diagnostic imaging procedures requiring contrast enhancement.
Product is in peak lifecycle phase with moderate competitive pressure (30%), suggesting stable revenue but limited team expansion opportunities.
X-Ray Contrast Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Currently zero linked jobs exist for this product, indicating a small or mature commercial footprint at Martin Pharmaceuticals. Working on CARBON DIOXIDE, USP offers stability in a diagnostic imaging niche but limited growth trajectory or team scaling opportunities.